INTRESO
20.6.2024 08:01:34 CEST | Business Wire | Press release
International Treatment Solutions (INTRESO) Group has written to the EU Commission’s Standing Committee on Biocidal Products to highlight the availability of safe, effective and environmentally sustainable alternatives to sulfuryl fluoride, ahead of a 21 June meeting which will consider a ban of the chemical for the preservation treatment of wood [PT8], and as an insecticide and acaricide for the control of insects and arachnids [PT18].
On 21 June, representatives from EU Member States will vote on a proposal to ban the use of sulfuryl fluoride, an extremely harmful synthetic greenhouse gas with a global warming potential more than 4500 times that of carbon dioxide, for these fumigation purposes. In what amounts to an effective ban, the EU is considering withdrawing approvals for the continued biocidal use of sulfuryl fluoride, due to a lack of data on the potential risks to human health posed by the chemical.
INTRESO Group produces BLUEFUME™, a highly effective and environmentally sustainable drop-in replacement for sulfuryl fluoride. BLUEFUME™ is the latest iteration of a tried and tested chemical, HCN, successfully used around the world for decades. INTRESO Group’s product is fully approved in numerous markets including in the EU, UK, Australia, New Zealand, Malaysia, Morocco and South Africa. Most recently, it has been put through rigorous testing and approval processes in Australia in 2023, with subsequent regulatory approval demonstrating impressive results against the latest standards.
Effective and economical, BLUEFUME™ breaks down into naturally occurring substances, meaning it also has a far lower environmental footprint than sulfuryl fluoride.
Besides being a Biocidal Product, sulfuryl fluoride is also a Plant Protection Product for the treatment of tree logs exported from the EU. In which case, additionally, INTRESO Group’s proprietary product, Ethanedinitrile (EDN™), is a highly effective and environmentally sustainable drop-in replacement for sulfuryl fluoride and has already been approved for the fumigation of timber and wood products in countries including Australia, New Zealand, South Korea, Malaysia, Uruguay, South Africa and Turkey. EDN was also successfully used over successive years in the Czech Republic under emergency use authorization during their recent bark beetle outbreak. This demonstrates that other major agricultural exporters have moved faster than the EU in approving alternative chemicals which adhere to stringent modern safety and environmental standards.
Commenting on the potential new restrictions on the use of sulfuryl fluoride in the EU, Kade McConville, Executive Director of INTRESO Group said:
“The claims that there is no available and highly effective alternative to sulfuryl fluoride for biocidal and plant protection use are simply not true. Our products, including EDN™ and BLUEFUME, are drop-in replacements that have been shown to be efficient under a wider set of climatic conditions than sulfuryl fluoride.
With increasing evidence as to the harms to human health and the planet resulting from sulfuryl fluoride, it is vitally important that EU decision-makers consider and understand the fact that alternative solutions are readily available for use in European fumigation, and that whilst sulfuryl fluoride is a tool, it is not the only tool in the toolbox.
Ahead of this pivotal vote, I have written to the Commission to make clear that our innovative, environmentally sustainable solutions already provide an effective alternative to sulfuryl fluoride in forward-thinking countries with some of the strictest biosecurity standards, including Australia and New Zealand.”
Background
- Fumigation is essential to protect against risks of invasive pests from international trade in raw commodities, with Europe facing unprecedented levels of bark beetle breakouts in conifer forests1.
- Sulfuryl fluoride, the most widely used fumigant in the EU, has a Global Warming Potential (GWP) more than 4500 times that of carbon dioxide.
- Use of sulfuryl fluoride is increasingly globally.
- Negotiations on the EU’s F-Gas Regulation, adopted in March 2024, resulted in new monitoring and recapture requirements and considered a total ban.
- EDNTM has a GWP over 4400x lower than sulfuryl fluoride.
- For more information on INTRESO: www.intreso.com
| ____________________ | |
1 |
https://foresteurope.org/bark-beetle-outbreaks-in-forests-a-pan-european-view/ |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240619174501/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
